全文获取类型
收费全文 | 1343761篇 |
免费 | 96808篇 |
国内免费 | 3011篇 |
专业分类
耳鼻咽喉 | 19811篇 |
儿科学 | 40603篇 |
妇产科学 | 38935篇 |
基础医学 | 187846篇 |
口腔科学 | 40196篇 |
临床医学 | 113048篇 |
内科学 | 264472篇 |
皮肤病学 | 30459篇 |
神经病学 | 107325篇 |
特种医学 | 54241篇 |
外国民族医学 | 435篇 |
外科学 | 210160篇 |
综合类 | 31074篇 |
现状与发展 | 6篇 |
一般理论 | 437篇 |
预防医学 | 91831篇 |
眼科学 | 31577篇 |
药学 | 101023篇 |
2篇 | |
中国医学 | 2971篇 |
肿瘤学 | 77128篇 |
出版年
2018年 | 12139篇 |
2016年 | 10922篇 |
2015年 | 12268篇 |
2014年 | 17168篇 |
2013年 | 25834篇 |
2012年 | 33876篇 |
2011年 | 35864篇 |
2010年 | 21294篇 |
2009年 | 20699篇 |
2008年 | 34382篇 |
2007年 | 37638篇 |
2006年 | 38166篇 |
2005年 | 36931篇 |
2004年 | 35946篇 |
2003年 | 34788篇 |
2002年 | 34342篇 |
2001年 | 63997篇 |
2000年 | 65585篇 |
1999年 | 55437篇 |
1998年 | 14043篇 |
1997年 | 12759篇 |
1996年 | 12259篇 |
1995年 | 12247篇 |
1994年 | 11518篇 |
1992年 | 43001篇 |
1991年 | 41517篇 |
1990年 | 40788篇 |
1989年 | 39771篇 |
1988年 | 37151篇 |
1987年 | 36595篇 |
1986年 | 35065篇 |
1985年 | 33289篇 |
1984年 | 24932篇 |
1983年 | 21098篇 |
1982年 | 12679篇 |
1981年 | 11564篇 |
1979年 | 23979篇 |
1978年 | 17102篇 |
1977年 | 14833篇 |
1976年 | 13388篇 |
1975年 | 15281篇 |
1974年 | 18111篇 |
1973年 | 17606篇 |
1972年 | 16857篇 |
1971年 | 15779篇 |
1970年 | 14958篇 |
1969年 | 14411篇 |
1968年 | 13522篇 |
1967年 | 12089篇 |
1966年 | 11311篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
G.R. Iball D. Tolan G.R. Avery L.H. Cope T. Hoare H. Lambie A. Lowe R.J. de Noronha C.L. Roberts M.E. Wilkinson P. Woolfall 《Clinical radiology》2021,76(8):626.e13-626.e21
42.
43.
Kazuko Sakai Takayuki Takahama Mototsugu Shimokawa Koichi Azuma Masayuki Takeda Terufumi Kato Haruko Daga Isamu Okamoto Hiroaki Akamatsu Shunsuke Teraoka Akira Ono Tatsuo Ohira Toshihide Yokoyama Nobuyuki Yamamoto Kazuhiko Nakagawa Kazuto Nishio 《Molecular oncology》2021,15(1):126
The WJOG8815L phase II clinical study involves patients with non‐small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA (ctDNA) from patients with NSCLC that undergo treatment with the third‐generation EGFR‐TKI osimertinib. Plasma samples of 52 patients harboring the EGFR T790M mutation were obtained pretreatment (Pre), on day 1 of treatment cycle 4 (C4) or cycle 9 (C9), and at diagnosis of disease progression or treatment discontinuation (PD/stop). CtDNA was screened for EGFR‐TKI‐sensitizing mutations, the EGFR T790M mutation, and other genomic alterations using the cobas EGFR Mutation Test v2 (cobas), droplet digital PCR (ddPCR), and targeted deep sequencing. Analysis of the sensitizing—and T790M—EGFR mutant fractions (MFs) was used to determine tumor mutational burden. Both MFs were found to decrease during treatment, whereas rebound of the sensitizing EGFR MF was observed at PD/stop, suggesting that osimertinib targeted both T790M mutation‐positive tumors and tumors with sensitizing EGFR mutations. Significant differences in the response rates and progression‐free survival were observed between the sensitizing EGFR MF‐high and sensitizing EGFR MF‐low groups (cutoff: median) at C4. In conclusion, ctDNA monitoring for sensitizing EGFR mutations at C4 is suitable for predicting the treatment outcomes in NSCLC patients receiving osimertinib (Clinical Trial Registration No.: UMIN000022076).
Abbreviations
- CIs
- confidence intervals
- ctDNA
- circulating tumor DNA
- ddPCR
- droplet digital PCR
- EGFR
- epidermal growth factor receptor
- MFs
- mutant fractions
- NGS
- next‐generation sequencing
- NSCLC
- non‐small cell lung cancer
- ORR
- overall response rate
- OS
- overall survival
- PD
- progressive disease
- PFS
- progression‐free survival
- PR
- partial response
- SD
- stable disease
- TKI
- tyrosine kinase inhibitor
44.
B.R. Mussmann S.D. Mørup P.M. Skov S. Foley A.S. Brenøe F. Eldahl G.M. Jørgensen H. Precht 《Radiography》2021,27(1):1-7
IntroductionOrgan-based tube current modulation (OBTCM) is designed for anterior dose reduction in Computed Tomography (CT). The purpose was to assess dose reduction capability in chest CT using three organ dose modulation systems at different kVp settings. Furthermore, noise, diagnostic image quality and tumour detection was assessed.MethodsA Lungman phantom was scanned with and without OBTCM at 80–135/140 kVp using three CT scanners; Canon Aquillion Prime, GE Revolution CT and Siemens Somatom Flash. Thermo-luminescent dosimeters were attached to the phantom surface and all scans were repeated five times. Image noise was measured in three ROIs at the level of the carina. Three observers visually scored the images using a fivestep scale. A Wilcoxon Signed-Rank test was used for statistical analysis of differences.ResultsUsing the GE revolution CT scanner, dose reductions between 1.10 mSv (12%) and 1.56 mSv (24%) (p < 0.01) were found in the anterior segment and no differences posteriorly and laterally. Total dose reductions between 0.64 (8%) and 0.91 mSv (13%) were found across kVp levels (p < 0.00001). Maximum noise increase with OBTCM was 0.8 HU. With the Canon system, anterior dose reductions of 6–10% and total dose reduction of 0.74–0.76 mSv across kVp levels (p < 0.001) were found with a maximum noise increase of 1.1 HU. For the Siemens system, dose increased by 22–51% anteriorly; except at 100 kVp where no dose difference was found. Noise decreased by 1 to 1.5 HU.ConclusionOrgan based tube current modulation is capable of anterior and total dose reduction with minimal loss of image quality in vendors that do not increase posterior dose.Implications for practiceThis research highlights the importance of being familiar with dose reduction technologies. 相似文献
45.
46.
47.
Syed S. Razi Joy A. Stephens-McDonnough Safi Haq Michael Fabbro Aliercy Nunez Sanchez Richard H. Epstein Nestor R. Villamizar Dao M. Nguyen 《The Journal of thoracic and cardiovascular surgery》2021,161(5):1689-1701
ObjectiveTo evaluate differences in postoperative pain control and opioids requirement in thoracic surgical patients following implementation of an Enhanced Recovery after Thoracic Surgery protocol with a comprehensive postoperative pain management strategy.Material and MethodsA retrospective analysis of a prospectively maintained database of patients undergoing pulmonary resections by robotic thoracoscopy or thoracotomy from January 1, 2017, to January 31, 2019, was conducted. Multimodal pain management strategy (opioid-sparing analgesics, infiltration of liposomal bupivacaine to intercostal spaces and surgical sites, and elimination of thoracic epidural analgesia use in thoracotomy patients) was implemented as part of Enhanced Recovery after Thoracic Surgery on February 1, 2018. Outcome metrics including patient-reported pain levels, in-hospital and postdischarge opioids use, postoperative complications, and length of stay were compared before and after protocol implementation.ResultsIn total, 310 robotic thoracoscopy and 62 thoracotomy patients met the inclusion criteria. This pain management strategy was associated with significant reduction of postoperative pain in both groups with an overall reduction of postoperative opioids requirement. Median in-hospital opioids use (morphine milligram equivalent per day) was reduced from 30 to 18.36 (P = .009) for the robotic thoracoscopy group and slightly increased from 15.48 to 21.0 (P = .27) in the thoracotomy group. More importantly, median postdischarge opioids prescribed (total morphine milligram equivalent) was significantly reduced from 480.0 to 150.0 (P < .001) and 887.5 to 150.0 (P < .001) for the thoracoscopy and thoracotomy groups, respectively. Similar short-term perioperative outcomes were observed in both groups before and following protocol implementation.ConclusionsImplementation of Enhanced Recovery after Thoracic Surgery allows safe elimination of epidural use, better pain control, and less postoperative opioids use, especially a drastic reduction of postdischarge opioid need, without adversely affecting outcomes. 相似文献
48.
49.
Andreas Glenthj Lasse H. Jakobsen Henrik Sengelv Syed A. Ahmad Kristian Qvist Annika Rewes Christian B. Poulsen Ulrik M. Overgaard Ingolf Mlle Marianne T. Severinsen Casper N. Strandholdt Jack Maibom Annette R. Kodahl Jesper Ryg Pernille Ravn Isik S. Johansen Sren N. Hels Sren Jensen‐Fangel Jacek Kisielewicz Lothar Wiese Marie Helleberg Ole Kirk Michael R. Clausen Henrik Frederiksen 《European journal of haematology》2021,106(1):72-81
50.
Castaldelli-Maia João Mauricio Hofmann Caio Chagas Antonio Carlos Palandri Liprandi Alvaro Sosa Alcocer Alejandro Andrade Laura H. Wielgosz Andreas 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》2021,35(3):441-454
Cardiovascular Drugs and Therapy - Major depressive disorder (MDD) and anxiety disorders (AD) are both highly prevalent among individuals with arrhythmia, ischemic heart disease, heart failure,... 相似文献